BusinesseFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological EffectsBy Nasdaq OMXNov 10, 2017, 3:00 PM UTC
BusinessThe Jackson Laboratory and Seven Bridges Collaborate to Build Centralized Data Platform to Advance Cancer ResearchBy Nasdaq OMXOct 17, 2017, 11:58 AM UTC
BusinesseFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal CancerBy Nasdaq OMXOct 4, 2017, 2:00 PM UTC
BusinessSurgical Oncologists and Oncology Health Care Professionals Come Together in Seattle to Discuss Groundbreaking Research and Advancements in the Surgical Treatment of CancerBy Nasdaq OMXFeb 15, 2017, 4:22 PM UTC
